Low-dose cytosine-arabinoside in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Low-dose cytosine-arabinoside in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

Authors:	H. J. Weh R. Zschaber D. K. Hossfeld

Affiliation:	(1) Department of Oncology and Hematology, University of Hamburg, Martinistr. 52, D-2000 Hamburg 20, Federal Republic of Germany

Abstract:	Summary Ten AML- and two MDS-patients in whom conventional chemotherapy was contraindicated or ineffective were treated with low dose ARA-C, 10 mg/m² per 12^hs.c. for 2–4 weeks. Seven patients obtained a complete and two a partial remission. Our findings suggest that low dose ARA-C may act both by induction of differentiation and/or inhibition of proliferation.Supported by the Hamburger Krebsgesellschaft

Keywords:	AML MDS Low dose ARA-C
本文献已被 SpringerLink 等数据库收录！